top of page

10 September |  2021

Prilenia to Present at Upcoming Virtual Healthcare Events 

Naarden, NL, 10 September 2021 Prilenia Therapeutics B.V., a clinical stage biotech company focused on developing novel treatments for neurodegenerative and neurodevelopmental disorders, today announced that Dr Michael R. Hayden, MD, PhD Chief Executive Officer, and Henk Schuring, Chief Regulatory and Commercialization Officer will be presenting at the following events in September:

  • European Huntington's Disease Network (EHDN) 2021 Remote Meeting on Friday, September 10, 2021, at 8:45am ET. Registration Link: click here


  • H.C. Wainwright 23rd Annual Global Investment Conference, 13 – 15 September. The presentation will be available on-demand through the H.C. Wainwright conference portal. Registration Link: click here

  • Cantor Virtual Global Healthcare Conference on Thursday, September 30, 2021. The Fireside chat will start at 8:40am ET. Registration Link: click here 

They will be sharing updates on the company and the ongoing clinical trials of pridopidine, the company’s lead asset, in Huntington’s Disease (HD) and Amyotrophic Lateral Sclerosis (ALS)

PROOF-HD, Prilenia’s global phase 3 study is currently the only drug in late-stage development that is assessing clinical progression of HD as measured by Total Functional Capacity (TFC). To HD patients and their families, functional capacity translates to a patient’s ability to maintain their occupation, continue to manage their daily lives and live independently for longer. In addition to PROOF-HD, pridopidine is also being evaluated in the first ALS platform trial at the Healey Center for ALS at the Massachusetts General Hospital. 

The above listed dates are subject to change. Details on presentation times or changes to presentation dates can be found on the Company's website. Please check for the latest information.

For further information, please contact:

Prilenia Therapeutics

Limor Ben Har, COO

Instinctif Partners
Melanie Toyne-Sewell / Agnes Stephens
T: +44 (0) 207 457 2020

bottom of page